BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/5/2026 9:11:01 AM | Browse: 15 | Download: 2
| Category |
Obstetrics & Gynecology |
| Manuscript Type |
Minireviews |
| Article Title |
Stem cell-based therapy for premature ovarian insufficiency: From mechanisms to clinical translation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li-Chun Weng, Shu-Ping Lyu and Hai-Yan Peng |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82301854, 82603233 |
| Youth Clinical Research Program of the Shanghai Municipal Health Commission |
20264Y0163 |
| Fundamental Research Funds for the Central Universities |
YG2026QNA50 |
|
| Corresponding Author |
Shu-Ping Lyu, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China. lv0217shuping@163.com |
| Key Words |
Premature ovarian insufficiency; Stem cell therapy; Mesenchymal stem cells; Ovarian regeneration; Clinical studies |
| Core Tip |
Premature ovarian insufficiency, characterized by ovarian dysfunction before age 40, causes infertility, menopausal symptoms, and long-term health risks, while hormonal therapy does not restore ovarian reserve or fertility. Stem cell-based therapies show regenerative potential, particularly mesenchymal stem/stromal cells and extracellular vesicles, through anti-apoptotic, antioxidant, angiogenic, immunomodulatory, and paracrine effects. Emerging gene-modified cells and cell-free products may enhance therapeutic precision and translational feasibility. However, clinical evidence remains limited and heterogeneous. Future progress requires mechanism-guided optimization, standardized manufacturing and potency assessment, appropriate delivery strategies, and rigorously designed randomized controlled trials to establish long-term safety and efficacy. |
| Citation |
Weng LC, Lyu SP, Peng HY. Stem cell-based therapy for premature ovarian insufficiency: From mechanisms to clinical translation. World J Stem Cells 2026; In press
|
| PDF |
127499-in-press.pdf
|
 |
Received |
|
2026-08-31 07:16 |
|
Peer-Review Started |
|
2026-08-31 07:16 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-09-08 03:14 |
|
Revised |
|
2026-09-22 08:36 |
|
Publication Fee Transferred |
|
2026-10-21 10:54 |
|
Second Decision by Editor |
|
2026-10-23 11:31 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-11-05 09:11 |
|
Articles in Press |
|
2026-11-05 09:11 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
|
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
